118TH CONGRESS 2D SESSION **S**.

To provide for a study by the National Academies of Sciences, Engineering, and Medicine on the prevalence and mortality of cancer among individuals who served as active duty aircrew in the Armed Forces, and for other purposes.

IN THE SENATE OF THE UNITED STATES

Mr. KELLY (for himself and Mr. COTTON) introduced the following bill; which was read twice and referred to the Committee on ______

A BILL

- To provide for a study by the National Academies of Sciences, Engineering, and Medicine on the prevalence and mortality of cancer among individuals who served as active duty aircrew in the Armed Forces, and for other purposes.
 - 1 Be it enacted by the Senate and House of Representa-
 - 2 tives of the United States of America in Congress assembled,

3 SECTION 1. SHORT TITLE.

4 This Act may be cited as the "ACES Act".

SEC. 2. NATIONAL ACADEMIES STUDY ON PREVALENCE AND MORTALITY OF CANCER AMONG INDI VIDUALS WHO SERVED AS ACTIVE DUTY AIR CREW IN THE ARMED FORCES.

(a) IN GENERAL.—The Secretary of Veterans Affairs
shall enter into an agreement with the National Academies
of Sciences, Engineering, and Medicine (in this section referred to as the "National Academies"), under which the
National Academies shall conduct a study on the prevalence and mortality of cancers among covered individuals.
(b) STUDY.—The study required under subsection (a)

11 (b) STUDY.—The study required under subsection (a)
12 shall—

(1) identify exposures associated with military
occupations of covered individuals, including relating
to chemicals, compounds, agents, and other phenomena;

17 (2) review the literature to determine associa18 tions between exposures referred to in paragraph (1)
19 and the incidence or prevalence of overall cancer
20 morbidity, overall cancer mortality, and increased in21 cidence or prevalence of—

- 22 (A) brain cancer;
- 23 (B) colon and rectal cancers;
- 24 (C) kidney cancer;
- 25 (D) lung cancer;
- 26 (E) melanoma skin cancer;

BAG24411 37D

S.L.C.

3

	3
1	(F) non-Hodgkin lymphoma;
2	(G) pancreatic cancer;
3	(H) prostate cancer;
4	(I) testiscular cancer;
5	(J) thyroid cancer;
6	(K) urinary bladder cancer; and
7	(L) other cancers as determined appro-
8	priate by the Secretary of Veterans Affairs, in
9	consultation with the National Academies; and
10	(3) determine, to the extent possible, the preva-
11	lence of and mortality from the cancers specified in
12	paragraph (2) among covered individuals by using
13	available sources of data, which may include—
14	(A) health care and other administrative
15	databases of the Department of Veterans Af-
16	fairs, the Department of Defense, and the indi-
17	vidual Services, respectively;
18	(B) the national death index maintained by
19	the National Center for Health Statistics of the
20	Centers for Disease Control and Prevention;
21	and
22	(C) the study conducted under section 750
23	of the William M. (Mac) Thornberry National
24	Defense Authorization Act for Fiscal Year 2021
25	(Public Law 116–283; 134 Stat. 3716).

4

(c) REPORT.—At the conclusion of the study required
 under subsection (a), the National Academies shall submit
 to the Secretary and to the Committee on Veterans' Af fairs of the Senate and the Committee on Veterans' Af fairs of the House of Representatives a report containing
 the results of the study described in subsection (b).

7 (d) COVERED INDIVIDUAL DEFINED.—In this sec8 tion, the term "covered individual" means an individual
9 who served on active duty in the Army, Navy, Air Force,
10 or Marine Corps as an aircrew member of a fixed-wing
11 aircraft, including as a pilot, navigator, weapons systems
12 operator, aircraft system operator, or any other crew
13 member who regularly flew in a fixed-wing aircraft.